Indian drugmaker Dr Reddy's slips on margin, semaglutide supply woes

• Stock dropped to 1,130 rupees, its lowest level in over one year
• The company faced supply disruptions for semaglutide, a key diabetes and weight-loss medication
• Dr Reddy's was the worst performer on both the pharma index and the benchmark Nifty 50 index

Summary: Dr Reddy's Laboratories Stock Decline

Key Developments:

Dr. Reddy's Laboratories (REDY.NS) shares fell 4.4% on Thursday, July 23, marking the stock's lowest level in over one year at 1,130 rupees. The Indian pharmaceutical company became the top loser on both the pharma index and the benchmark Nifty 50.

Primary Catalysts:

The decline followed disappointing quarterly results that missed analyst expectations, prompting multiple brokerages to downgrade their earnings forecasts for the drugmaker. Additionally, the company is facing supply disruptions for semaglutide, a key diabetes and weight-loss medication that has seen surging global demand.

Market Context:

The weaker-than-expected performance highlights operational challenges for one of India's leading pharmaceutical manufacturers. The margin pressures and supply chain issues with semaglutide—a high-value product in the rapidly growing GLP-1 drug category—raise concerns about near-term profitability and revenue growth.

Sector Impact:

As the top decliner in the pharmaceutical index, Dr. Reddy's weakness may signal broader concerns about margin compression in India's generics sector or specific execution challenges at the company level. The semaglutide supply problems are particularly notable given the massive market opportunity for generic versions of popular branded drugs like Ozempic and Wegovy.

Investor Implications:

The brokerage downgrades suggest reduced confidence in Dr. Reddy's near-term earnings trajectory. Investors should monitor how quickly the company can resolve its semaglutide supply issues and whether margin pressures persist in upcoming quarters. The one-year low presents potential value for long-term investors, though near-term headwinds appear significant.